New lung drug faces off against standard treatment in major trial
NCT ID NCT07284602
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 16 times
Summary
This study tests a new drug, deupirfenidone, against the current standard treatment pirfenidone for people with idiopathic pulmonary fibrosis (IPF), a lung disease that gets worse over time. About 1,100 adults will take one of the two drugs three times a day for up to three years, and neither they nor their doctors will know which one they are getting. The main goal is to see if deupirfenidone slows the decline in lung function better than pirfenidone. Participants cannot be on other IPF treatments during the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.